To Examine the Effect of Horizant (Gabapentin Enacarbil) in Primary Restless Legs Syndrome (RLS) Patients Who Are on Dopaminergic Agents and Exhibiting Augmentation

Trial Profile

To Examine the Effect of Horizant (Gabapentin Enacarbil) in Primary Restless Legs Syndrome (RLS) Patients Who Are on Dopaminergic Agents and Exhibiting Augmentation

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Gabapentin enacarbil (Primary)
  • Indications Restless legs syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Mar 2018 Planned End Date changed from 1 Feb 2019 to 1 Jun 2019.
    • 30 Mar 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.
    • 13 Feb 2017 Planned number of patients changed from 20 to 50.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top